Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Cash & Current Investments: 2018-2025

Historic Cash & Current Investments for Dr Reddys Laboratories (RDY) over the last 8 years, with Mar 2025 value amounting to $678.0 million.

  • Dr Reddys Laboratories' Cash & Current Investments fell 30.60% to $678.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $3.0 billion, marking a year-over-year increase of 7.36%. This contributed to the annual value of $678.0 million for FY2025, which is 30.60% down from last year.
  • As of FY2025, Dr Reddys Laboratories' Cash & Current Investments stood at $678.0 million, which was down 30.60% from $977.0 million recorded in FY2024.
  • Dr Reddys Laboratories' 5-year Cash & Current Investments high stood at $977.0 million for FY2024, and its period low was $473.0 million during FY2021.
  • Moreover, its 3-year median value for Cash & Current Investments was $752.0 million (2023), whereas its average is $802.3 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first surged by 38.71% in 2021, then crashed by 30.60% in 2025.
  • Dr Reddys Laboratories' Cash & Current Investments (Yearly) stood at $473.0 million in 2021, then increased by 23.68% to $585.0 million in 2022, then rose by 28.55% to $752.0 million in 2023, then climbed by 29.92% to $977.0 million in 2024, then plummeted by 30.60% to $678.0 million in 2025.